SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regen Therapeutics (colostrinin for use in Alzheimer's)
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  
From: edwards458/31/2005 11:14:25 AM
   of 4
 
ReGen Therapeutics receives another US patent for Colostrinin treatment

LONDON (AFX) - ReGen Therapeutics PLC said its Colostrinin treatment has
been granted a US patent for its use in the induction of cytokines that could
potentially benefit sufferers of Alzheimer's disease.
Cytokines are molecules that are involved in communication between cells.
In June, ReGen said a study highlighted the positive effects of Colostrinin
on Alzheimer's patients.
ReGen said it now holds rights to five different patents relating to
Colostrinin.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFileNext 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News